Creative Testing Solutions Selects LifeTrak® for Tampa Lab
Prestigious blood testing laboratory expands use of Mediware’s blood donor management system to support additional facility and growing business.
LENEXA, KS, March 16, 2011 - Mediware Information Systems, Inc. (Nasdaq: MEDW) announced that Creative Testing Solutions (CTS) has selected the LifeTrak® software to manage blood testing procedures in the company’s Tampa, Fla. location. The selection, which was the result of a thorough selection process including most major laboratory systems, expands Mediware’s presence in the blood laboratory services industry and represents another major win for the modern and flexible LifeTrak software.
The LifeTrak software includes Donor, Lab and Distribution modules to provide the most comprehensive blood management solution available for blood centers, testing facilities and other organizations collecting, manufacturing or testing blood products. LifeTrak is used by many of the most prestigious blood suppliers including the BloodCenter of Wisconsin and Carter BloodCare, where the product was originally developed.
CTS, which formed January 1, 2010 as a joint venture between Blood Systems Laboratories Donor Testing Laboratories and Florida Blood Services Donor Sample Testing Laboratory, tests over 25 percent of the nation’s blood supply. CTS locations in Bedford, Texas and Tempe, Ariz., have utilized LifeTrak for over ten years to process over 3 million blood units annually for customers throughout the United States. The addition of the Tampa location adds another 1.1 million annual units being processed by Mediware software.
“Our intense focus on blood center over the past few years has proven to be a solid investment, for Mediware and our customers,” said Thomas Mann, Mediware’s president and chief executive officer. “Our strategy of continued investment in new product development and acquisitions provides the industry a comprehensive suite of software solutions and services. I believe this has resulted in many of our new customers as well as the expansion of existing relationships with market leading organizations such as CTS.”
CTS currently performs donor testing, specialized testing and component quality control services for over 100 blood center and hospital customers located throughout the country.
LifeTrak is 510(k) cleared by the U.S. Food and Drug Administration (US FDA) as a medical device.
Mediware delivers interoperable best-of-breed software systems that integrate with electronic medical records to improve efficiencies and address safety concerns enabling healthcare organizations to improve care processes while decreasing costs. Core Mediware solutions include blood management technologies for hospitals and blood centers; medication management solutions for hospitals, behavioral health facilities, infusion and specialty pharmacy providers; and business intelligence-based performance management solutions for clinical, regulatory and financial aspects of the broader healthcare market. For more information about Mediware products and services, visit our web site at www.mediware.com.
Certain statements in this press release may constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as the same may be amended from time to time (the "Act") and are intended to be covered by the safe harbor created thereby. Such forward-looking statements are not necessarily based on historical facts and involve known and unknown risks, uncertainties and other factors which may cause the actual results of the Company to be materially different from any future results expressed or implied by such forward looking statements. These risk and uncertainties include but are not limited to those disclosed in the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company does not intend to, and undertakes no obligation to, update forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial condition or business over time. The Company regularly posts important information to the investor relations section of its website.